1
|
Zhong Q, Gao W, Du F and Wang X:
Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the
polyubiquitination of Mcl-1 and regulates apoptosis. Cell.
121:1085–1095. 2005. View Article : Google Scholar : PubMed/NCBI
|
2
|
Schreiber A and Peter M: Substrate
recognition in selective autophagy and the ubiquitin-proteasome
system. Biochim Biophys Acta. 1843:163–181. 2014. View Article : Google Scholar : PubMed/NCBI
|
3
|
Rotin D and Kumar S: Physiological
functions of the HECT family of ubiquitin ligases. Nat Rev Mol Cell
Biol. 10:398–409. 2009. View
Article : Google Scholar : PubMed/NCBI
|
4
|
Schrader EK, Harstad KG and Matouschek A:
Targeting proteins for degradation. Nat Chem Biol. 5:815–822. 2009.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Teixeira LK and Reed SI: Ubiquitin ligases
and cell cycle control. Annu Rev Biochem. 82:387–414. 2013.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Aleidi SM, Howe V, Sharpe LJ, Yang A, Rao
G, Brown AJ and Gelissen IC: The E3 ubiquitin ligases, HUWE1 and
NEDD4-1, are involved in the post-translational regulation of the
ABCG1 and ABCG4 lipid transporters. J Biol Chem. 290:24604–24613.
2015. View Article : Google Scholar : PubMed/NCBI
|
7
|
Clague MJ, Liu H and Urbé S: Governance of
endocytic trafficking and signaling by reversible ubiquitylation.
Dev Cell. 23:457–467. 2012. View Article : Google Scholar : PubMed/NCBI
|
8
|
Scheffner M and Kumar S: Mammalian HECT
ubiquitin-protein ligases: Biological and pathophysiological
aspects. Biochim Biophys Acta. 1843:61–74. 2014. View Article : Google Scholar : PubMed/NCBI
|
9
|
Sun Y: Targeting E3 ubiquitin ligases for
cancer therapy. Cancer Biol Ther. 2:623–629. 2003. View Article : Google Scholar : PubMed/NCBI
|
10
|
Scheffner M and Staub O: HECT E3s and
human disease. BMC Biochem. 8 (Suppl 1):S62007. View Article : Google Scholar : PubMed/NCBI
|
11
|
Leboucher GP, Tsai YC, Yang M, Shaw KC,
Zhou M, Veenstra TD, Glickman MH and Weissman AM: Stress-induced
phosphorylation and proteasomal degradation of mitofusin 2
facilitates mitochondrial fragmentation and apoptosis. Mol Cell.
47:547–557. 2012. View Article : Google Scholar : PubMed/NCBI
|
12
|
Zhou X, Li TT, Feng X, Hsiang E, Xiong Y,
Guan KL and Lei QY: Targeted polyubiquitylation of RASSF1C by the
Mule and SCFβ-TrCP ligases in response to DNA damage. Biochem J.
441:227–236. 2012. View Article : Google Scholar : PubMed/NCBI
|
13
|
Zhang J, Kan S, Huang B, Hao Z, Mak TW and
Zhong Q: Mule determines the apoptotic response to HDAC inhibitors
by targeted ubiquitination and destruction of HDAC2. Genes Dev.
25:2610–2618. 2011. View Article : Google Scholar : PubMed/NCBI
|
14
|
Chen D, Kon N, Li M, Zhang W, Qin J and Gu
W: ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor.
Cell. 121:1071–1083. 2005. View Article : Google Scholar : PubMed/NCBI
|
15
|
Adhikary S, Marinoni F, Hock A, Hulleman
E, Popov N, Beier R, Bernard S, Quarto M, Capra M, Goettig S, et
al: The ubiquitin ligase HectH9 regulates transcriptional
activation by Myc and is essential for tumor cell proliferation.
Cell. 123:409–421. 2005. View Article : Google Scholar : PubMed/NCBI
|
16
|
Hall JR, Kow E, Nevis KR, Lu CK, Luce KS,
Zhong Q and Cook JG: Cdc6 stability is regulated by the Huwe1
ubiquitin ligase after DNA damage. Mol Biol Cell. 18:3340–3350.
2007. View Article : Google Scholar : PubMed/NCBI
|
17
|
Herold S, Hock A, Herkert B, Berns K,
Mullenders J, Beijersbergen R, Bernards R and Eilers M: Miz1 and
HectH9 regulate the stability of the checkpoint protein, TopBP1.
EMBO J. 27:2851–2861. 2008. View Article : Google Scholar : PubMed/NCBI
|
18
|
Yang Y, Do H, Tian X, Zhang C, Liu X, Dada
LA, Sznajder JI and Liu J: E3 ubiquitin ligase Mule ubiquitinates
Miz1 and is required for TNFalpha-induced JNK activation. Proc Natl
Acad Sci USA. 107:13444–13449. 2010. View Article : Google Scholar : PubMed/NCBI
|
19
|
Parsons JL, Tait PS, Finch D, Dianova II,
Edelmann MJ, Khoronenkova SV, Kessler BM, Sharma RA, McKenna WG and
Dianov GL: Ubiquitin ligase ARF-BP1/Mule modulates base excision
repair. EMBO J. 28:3207–3215. 2009. View Article : Google Scholar : PubMed/NCBI
|
20
|
Liu Z, Miao D, Xia Q, Hermo L and Wing SS:
Regulated expression of the ubiquitin protein ligase,
E3(Histone)/LASU1/Mule/ARF-BP1/HUWE1, during spermatogenesis. Dev
Dyn. 236:2889–2898. 2007. View Article : Google Scholar : PubMed/NCBI
|
21
|
Zhao X, Heng JI, Guardavaccaro D, Jiang R,
Pagano M, Guillemot F, Iavarone A and Lasorella A: The HECT-domain
ubiquitin ligase Huwe1 controls neural differentiation and
proliferation by destabilizing the N-Myc oncoprotein. Nat Cell
Biol. 10:643–653. 2008. View
Article : Google Scholar : PubMed/NCBI
|
22
|
Qi CF, Kim YS, Xiang S, Abdullaev Z,
Torrey TA, Janz S, Kovalchuk AL, Sun J, Chen D, Cho WC, et al:
Characterization of ARF-BP1/HUWE1 Interactions with CTCF, MYC, ARF
and p53 in MYC-Driven B Cell Neoplasms. Int J Mol Sci.
13:6204–6219. 2012. View Article : Google Scholar : PubMed/NCBI
|
23
|
Faiola F, Liu X, Lo S, Pan S, Zhang K,
Lymar E, Farina A and Martinez E: Dual regulation of c-Myc by p300
via acetylation-dependent control of Myc protein turnover and
coactivation of Myc-induced transcription. Mol Cell Biol.
25:10220–10234. 2005. View Article : Google Scholar : PubMed/NCBI
|
24
|
Vervoorts J, Lüscher-Firzlaff JM, Rottmann
S, Lilischkis R, Walsemann G, Dohmann K, Austen M and Lüscher B:
Stimulation of c-MYC transcriptional activity and acetylation by
recruitment of the cofactor CBP. EMBO Rep. 4:484–490. 2003.
View Article : Google Scholar : PubMed/NCBI
|
25
|
Bernassola F, Karin M, Ciechanover A and
Melino G: The HECT family of E3 ubiquitin ligases: Multiple players
in cancer development. Cancer Cell. 14:10–21. 2008. View Article : Google Scholar : PubMed/NCBI
|
26
|
Myant KB, Cammareri P, Hodder MC, Wills J,
Von Kriegsheim A, Győrffy B, Rashid M, Polo S, Maspero E, Vaughan
L, et al: HUWE1 is a critical colonic tumour suppressor gene that
prevents MYC signalling, DNA damage accumulation and tumour
initiation. EMBO Mol Med. 9:181–197. 2017. View Article : Google Scholar : PubMed/NCBI
|
27
|
Peter S, Bultinck J, Myant K, Jaenicke LA,
Walz S, Müller J, Gmachl M, Treu M, Boehmelt G, Ade CP, et al:
Tumor cell-specific inhibition of MYC function using small molecule
inhibitors of the HUWE1 ubiquitin ligase. EMBO Mol Med.
6:1525–1541. 2014. View Article : Google Scholar : PubMed/NCBI
|
28
|
Rhodes DR, Yu J, Shanker K, Deshpande N,
Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM:
ONCOMINE: A cancer microarray database and integrated data-mining
platform. Neoplasia. 6:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
|
29
|
Rhodes DR, Kalyana-Sundaram S, Mahavisno
V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ,
Kincead-Beal C, Kulkarni P, et al: Oncomine 3.0: Genes, pathways,
and networks in a collection of 18,000 cancer gene expression
profiles. Neoplasia. 9:166–180. 2007. View Article : Google Scholar : PubMed/NCBI
|
30
|
Murat A, Migliavacca E, Gorlia T, Lambiv
WL, Shay T, Hamou MF, de Tribolet N, Regli L, Wick W, Kouwenhoven
MC, et al: Stem cell-related ‘self-renewal’ signature and high
epidermal growth factor receptor expression associated with
resistance to concomitant chemoradiotherapy in glioblastoma. J Clin
Oncol. 26:3015–3024. 2008. View Article : Google Scholar : PubMed/NCBI
|
31
|
Bredel M, Bredel C, Juric D, Harsh GR,
Vogel H, Recht LD and Sikic BI: Functional network analysis reveals
extended gliomagenesis pathway maps and three novel MYC-interacting
genes in human gliomas. Cancer Res. 65:8679–8689. 2005. View Article : Google Scholar : PubMed/NCBI
|
32
|
Sun L, Hui AM, Su Q, Vortmeyer A,
Kotliarov Y, Pastorino S, Passaniti A, Menon J, Walling J, Bailey
R, et al: Neuronal and glioma-derived stem cell factor induces
angiogenesis within the brain. Cancer Cell. 9:287–300. 2006.
View Article : Google Scholar : PubMed/NCBI
|
33
|
Finak G, Bertos N, Pepin F, Sadekova S,
Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu
A, et al: Stromal gene expression predicts clinical outcome in
breast cancer. Nat Med. 14:518–527. 2008. View Article : Google Scholar : PubMed/NCBI
|
34
|
Gyorffy B, Lánczky A and Szállási Z:
Implementing an online tool for genome-wide validation of
survival-associated biomarkers in ovarian-cancer using microarray
data from 1287 patients. Endocr Relat Cancer. 19:197–208. 2012.
View Article : Google Scholar : PubMed/NCBI
|
35
|
Mizuno H, Kitada K, Nakai K and Sarai A:
PrognoScan: A new database for meta-analysis of the prognostic
value of genes. BMC Med Genomics. 2:182009. View Article : Google Scholar : PubMed/NCBI
|
36
|
Franceschini A, Szklarczyk D, Frankild S,
Kuhn M, Simonovic M, Roth A, Lin J, Minguez P, Bork P, von Mering C
and Jensen LJ: STRING v9. 1: Protein-protein interaction networks,
with increased coverage and integration. Nucleic Acids Res 41
(Database Issue). D808–D815. 2013.
|
37
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
|
38
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
39
|
Beltran H, Prandi D, Mosquera JM, Benelli
M, Puca L, Cyrta J, Marotz C, Giannopoulou E, Chakravarthi BV,
Varambally S, et al: Divergent clonal evolution of
castration-resistant neuroendocrine prostate cancer. Nat Med.
22:298–305. 2016. View Article : Google Scholar : PubMed/NCBI
|
40
|
Kumar A, Coleman I, Morrissey C, Zhang X,
True LD, Gulati R, Etzioni R, Bolouri H, Montgomery B, White T, et
al: Substantial interindividual and limited intraindividual genomic
diversity among tumors from men with metastatic prostate cancer.
Nat Med. 22:369–378. 2016. View Article : Google Scholar : PubMed/NCBI
|
41
|
Hodis E, Watson IR, Kryukov GV, Arold ST,
Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C,
et al: A landscape of driver mutations in melanoma. Cell.
150:251–263. 2012. View Article : Google Scholar : PubMed/NCBI
|
42
|
Cancer Genome Atlas Research Network, ;
Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H,
Robertson AG, Pashtan I, Shen R, et al: Integrated genomic
characterization of endometrial carcinoma. Nature. 497:67–73. 2013.
View Article : Google Scholar : PubMed/NCBI
|
43
|
Campbell JD, Alexandrov A, Kim J, Wala J,
Berger AH, Pedamallu CS, Shukla SA, Guo G, Brooks AN, Murray BA, et
al: Distinct patterns of somatic genome alterations in lung
adenocarcinomas and squamous cell carcinomas. Nat Genet.
48:607–616. 2016. View Article : Google Scholar : PubMed/NCBI
|
44
|
Imielinski M, Berger AH, Hammerman PS,
Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M,
Sivachenko A, et al: Mapping the hallmarks of lung adenocarcinoma
with massively parallel sequencing. Cell. 150:1107–1120. 2012.
View Article : Google Scholar : PubMed/NCBI
|
45
|
Comprehensive molecular profiling of lung
adenocarcinoma, . Nature. 511:543–550. 2014. View Article : Google Scholar : PubMed/NCBI
|
46
|
Liang Y, Diehn M, Watson N, Bollen AW,
Aldape KD, Nicholas MK, Lamborn KR, Berger MS, Botstein D, Brown PO
and Israel MA: Gene expression profiling reveals molecularly and
clinically distinct subtypes of glioblastoma multiforme. Proc Natl
Acad Sci USA. 102:5814–5819. 2005. View Article : Google Scholar : PubMed/NCBI
|
47
|
Haslinger C, Schweifer N, Stilgenbauer S,
Döhner H, Lichter P, Kraut N, Stratowa C and Abseher R: Microarray
gene expression profiling of B-cell chronic lymphocytic leukemia
subgroups defined by genomic aberrations and VH mutation status. J
Clin Oncol. 22:3937–3949. 2004. View Article : Google Scholar : PubMed/NCBI
|
48
|
Bhattacharjee A, Richards WG, Staunton J,
Li C, Monti S, Vasa P, Ladd C, Beheshti J, Bueno R, Gillette M, et
al: Classification of human lung carcinomas by mRNA expression
profiling reveals distinct adenocarcinoma subclasses. Proc Natl
Acad Sci USA. 98:13790–13795. 2001. View Article : Google Scholar : PubMed/NCBI
|
49
|
Garber ME, Troyanskaya OG, Schluens K,
Petersen S, Thaesler Z, Pacyna-Gengelbach M, van de Rijn M, Rosen
GD, Perou CM, Whyte RI, et al: Diversity of gene expression in
adenocarcinoma of the lung. Proc Natl Acad Sci USA. 98:13784–13789.
2001. View Article : Google Scholar : PubMed/NCBI
|
50
|
Storz MN, van de Rijn M, Kim YH,
Mraz-Gernhard S, Hoppe RT and Kohler S: Gene expression profiles of
cutaneous B cell lymphoma. J Invest Dermatol. 120:865–870. 2003.
View Article : Google Scholar : PubMed/NCBI
|
51
|
Skotheim RI, Lind GE, Monni O, Nesland JM,
Abeler VM, Fosså SD, Duale N, Brunborg G, Kallioniemi O, Andrews PW
and Lothe RA: Differentiation of human embryonal carcinomas in
vitro and in vivo reveals expression profiles relevant to normal
development. Cancer Res. 65:5588–5598. 2005. View Article : Google Scholar : PubMed/NCBI
|
52
|
Luo JH, Yu YP, Cieply K, Lin F, Deflavia
P, Dhir R, Finkelstein S, Michalopoulos G and Becich M: Gene
expression analysis of prostate cancers. Mol Carcinog. 33:25–35.
2002. View Article : Google Scholar : PubMed/NCBI
|
53
|
Varambally S, Yu J, Laxman B, Rhodes DR,
Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ, et
al: Integrative genomic and proteomic analysis of prostate cancer
reveals signatures of metastatic progression. Cancer Cell.
8:393–406. 2005. View Article : Google Scholar : PubMed/NCBI
|
54
|
Detwiller KY, Fernando NT, Segal NH, Ryeom
SW, D'Amore PA and Yoon SS: Analysis of hypoxia-related gene
expression in sarcomas and effect of hypoxia on RNA interference of
vascular endothelial cell growth factor A. Cancer Res.
65:5881–5889. 2005. View Article : Google Scholar : PubMed/NCBI
|
55
|
Klonowska K, Czubak K, Wojciechowska M,
Handschuh L, Zmienko A, Figlerowicz M, Dams-Kozlowska H and
Kozlowski P: Oncogenomic portals for the visualization and analysis
of genome-wide cancer data. Oncotarget. 7:176–192. 2016. View Article : Google Scholar : PubMed/NCBI
|
56
|
Xie S, Shen C, Tan M, Li M, Song X and
Wang C: Systematic analysis of gene expression alterations and
clinical outcomes of adenylate cyclase-associated protein in
cancer. Oncotarget. 8:27216–27239. 2017.PubMed/NCBI
|
57
|
Stratton MR, Campbell PJ and Futreal PA:
The cancer genome. Nature. 458:719–724. 2009. View Article : Google Scholar : PubMed/NCBI
|
58
|
Beroukhim R, Mermel CH, Porter D, Wei G,
Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J,
Urashima M, et al: The landscape of somatic copy-number alteration
across human cancers. Nature. 463:899–905. 2010. View Article : Google Scholar : PubMed/NCBI
|
59
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
60
|
National Cancer Institute: Genomic Data
Commons Data Portal. https://portal.gdc.cancer.gov/August
11–2017
|